Form 8-K

8-K — PetVivo Holdings, Inc.

Accession: 0001493152-26-043641

Filed: 2026-09-22

Period: 2026-09-22

CIK: 0001512922

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001512922

2026-09-22

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

September

22, 2026

Date

of Report (Date of earliest event reported)

PETVIVO

HOLDINGS, INC.

(Exact

name of registrant as specified in its charter)

Nevada

001-40715

99-0363559

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

5151

Edina Industrial Blvd.

Suite

575

Edina,

Minnesota

55439

(Address

of principal executive offices)

(Zip

Code)

(952)

405-6216

Registrant’s

telephone number, including area code

Check

the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of

the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(g) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

PETV

OTCQX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

Resignation

of Joseph Jasper

Effective

September 22, 2026, Joseph Jasper resigned as a member of the Board of Directors (the “Board”) of PetVivo Holdings, Inc.,

a Nevada corporation (the “Company”). Mr. Jasper’s resignation was not the result of any disagreement with the Company

on any matter relating to the Company’s operations, policies or practices. The Board expresses its appreciation to Mr. Jasper for

his leadership, guidance and contributions during his tenure on the Board.

Appointment

of Michael K. Handley

Effective

September 22, 2026, the Board appointed Michael K. Handley as a director of the Company to fill the vacancy created by Mr. Jasper’s

resignation, thereby maintaining the size of the Board at six directors. Mr. Handley will serve until the next annual meeting of shareholders

and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.

Mr.

Handley is a life sciences executive and board director with more than 25 years of experience in the biotechnology, pharmaceutical and

medical device industries. He has raised more than $700 million in public and private capital, supported more than 80 global product

launches, and led or contributed to transactions with an aggregate value exceeding $4 billion. His experience includes corporate strategy

and governance, capital markets, investor relations, mergers and acquisitions, licensing, clinical development, regulatory affairs, commercialization

and global operations.

Mr.

Handley served as Chief Executive Officer and a director of Valion Bio, Inc. from March to August 2026 and as its Chief Operating Officer

and President of Statera Biopharma from February 2025 to March 2026. From July 2021 to February 2025, he served as President, Chief Executive

Officer and Chairman of Statera Biopharma, Inc. He previously served as Chief Executive Officer and a director of Immune Therapeutics,

Inc. from July 2019 to March 2020 and of Armis Biopharma from 2012 to 2018. Mr. Handley helped found Vessix Vascular, Inc. in 2011 and

served as its Vice President of Clinical, Quality and Regulatory until its acquisition by Boston Scientific Corporation in 2012. He also

served as Global Head of Regulatory at Acclarent, Inc. and held senior executive positions at Spectranetics Corporation, Accelapure Corporation,

Genentech, Inc., Amgen Inc. and Gliatech Inc.

Mr.

Handley graduated cum laude from Colorado State University with a B.S. in Molecular Biology and Physiology and minors in Chemistry and

Neuroanatomy. He attended the Executive MBA program at Pepperdine University and completed the Global C-Suite Program at the Wharton

School of the University of Pennsylvania. He has served on corporate and nonprofit boards, taught in Colorado State University’s

Regulatory Affairs Program, lectured at Drexel University’s LeBow College of Business, and is an inventor and author of issued

patents, published patent applications and peer-reviewed scientific publications.

Mr.

Handley’s extensive life sciences leadership experience, together with his background in capital raising, strategic transactions,

regulatory affairs and commercialization, were material factors in the Board’s determination that he is qualified to serve as a

director of the Company.

Mr.

Handley will initially serve as a non-employee director and receive compensation consistent with that of the Company’s other non-employee

directors, prorated for his period of service. The Company’s non-employee director compensation program is described in its Current

Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2025. His compensation for Board service may be adjusted

by the Board in connection with any subsequent employment by the Company or one of its subsidiaries.

There

are no arrangements or understandings between Mr. Handley and any other persons pursuant to which he was selected as a director of the

Company and there are no transactions or proposed transactions in which Mr. Handley has a direct or indirect interest requiring disclosure

under Item 404(a) of Regulation S-K or Item 5.02(d) of Form 8-K. Mr. Handley does not have any family relationship with any of the Company’s

directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer.

this time, Mr. Handley has not been appointed to any committees.

The

press release announcing his appointment is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

99.1

Press Release dated September 22, 2026

104

Cover

Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the

undersigned hereunto duly authorized.

PETVIVO

HOLDINGS, INC.

Date:

September 22, 2026

By:

/s/

John Lai

Name:

John

Lai

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

5151

Edina Industrial Blvd., Suite 575, Minneapolis, MN 55439 | (952) 405-6216 | www.petvivo.com

PRESS

RELEASE:

Michael

Handley Joins PetVivo Holdings, Inc. Board of Directors

MINNEAPOLIS, MN, US, September 22, 2026

— PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), together with its subsidiaries PetVivo Animal Health, Inc.,

Somatrix Technologies, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on the commercialization of innovative

medical devices and therapeutics for companion animals, today announced the appointment of Michael K. Handley to its Board of Directors,

effective September 22, 2026.

“We

are pleased to welcome Michael Handley to PetVivo’s Board of Directors,” said John Lai, Chief Executive Officer of PetVivo

Holdings, Inc. “Michael brings extensive experience in building life sciences companies, raising capital and guiding technologies

through development and commercialization. His perspective across biotechnology, pharmaceuticals and medical devices will be valuable

as we work to expand adoption of our products, evaluate strategic opportunities and build long-term shareholder value.”

Mr.

Handley is a life sciences executive and board director with more than 25 years of experience in the biotechnology, pharmaceutical and

medical device industries. He has raised more than $700 million in public and private capital, supported more than 80 global product

launches, and led or contributed to transactions with an aggregate value exceeding $4 billion. His experience spans corporate strategy

and governance, capital markets, mergers and acquisitions, licensing, clinical development, regulatory affairs and global commercialization.

Mr.

Handley most recently served as Chief Executive Officer and a director of Valion Bio, Inc. Previously, he was President, Chief Executive

Officer and Chairman of Statera Biopharma, Inc., and held chief executive and director roles at Immune Therapeutics, Corp and Armis Biopharma.

He also helped found Vessix Vascular, Inc., where he served as Vice President of Clinical, Quality and Regulatory until its acquisition

by Boston Scientific Corporation in 2012.

Mr.

Handley graduated cum laude from Colorado State University with a B.S. in Molecular Biology and Physiology. He attended the Executive

MBA program at Pepperdine University and completed the Global C-Suite Program at the Wharton School of the University of Pennsylvania.

“I

am excited to join PetVivo’s Board and work with John and the leadership team,” said Mr. Handley. “PetVivo’s

focus on bringing innovative technologies to veterinary medicine, together with the potential to develop applications in human health,

aligns closely with my experience in life sciences development and commercialization. I look forward to helping the Company evaluate

growth opportunities, develop strategic relationships and advance its business in ways that support veterinarians, the animals they care

for and, over time, potential human healthcare applications, while building long-term shareholder value.”

Mr.

Handley fills the vacancy created by Joseph Jasper’s resignation, effective September 22, 2026. The Board thanks Mr. Jasper for

his leadership, guidance and contributions during his tenure. Following these changes, the Board continues to consist of six directors.

About

PetVivo Holdings, Inc.

PetVivo

Holdings, Inc. (OTCQX: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI,

Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative

medical devices, biomaterials and therapeutics for animal and human health. The Company’s strategy is to leverage its proprietary

technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary

and human medicine.

PetVivo

has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade

secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product,

SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness

and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

Company

Contact

John

Lai, CEO

PetVivo

Holdings, Inc.

Contact

Tel

(952) 405-6216

Forward-Looking

Statements

The

foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements”

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended.

Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation

the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,”

“will,” “expect,” “project,” “estimate,” “anticipate,” “plan,”

“believe,” “potential,” “should,” “continue” or the negative versions of those words

or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements

are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties

and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the

Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities

and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking

statements, whether as a result of new information, future events or otherwise.

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (19165 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 4

Binary file (45450 bytes)

Download ex99-1_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.3

Cover

Sep. 22, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 22, 2026

Entity File Number

001-40715

Entity Registrant Name

PETVIVO

HOLDINGS, INC.

Entity Central Index Key

0001512922

Entity Tax Identification Number

99-0363559

Entity Incorporation, State or Country Code

Entity Address, Address Line One

5151

Edina Industrial Blvd.

Entity Address, Address Line Two

Suite

575

Entity Address, City or Town

Edina

Entity Address, State or Province

Entity Address, Postal Zip Code

55439

City Area Code

(952)

Local Phone Number

405-6216

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

PETV

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration